Primary Biliary Cholangitis (PBC) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Genfit, CymaBay, Mirum, Gilead, Eli Lilly, Ohara

 Breaking News
  • No posts were found

Primary Biliary Cholangitis (PBC) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Genfit, CymaBay, Mirum, Gilead, Eli Lilly, Ohara

November 07
21:51 2023
Primary Biliary Cholangitis (PBC) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Genfit, CymaBay, Mirum, Gilead, Eli Lilly, Ohara
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 28+ key pharma and biotech companies are working on 28+ pipeline drugs in the Primary Biliary Cholangitis (PBC) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Primary Biliary Cholangitis (PBC) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Primary Biliary Cholangitis Market. 

The Primary Biliary Cholangitis Pipeline report embraces in-depth commercial, regulatory, and Primary Biliary Cholangitis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Primary Biliary Cholangitis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Primary Biliary Cholangitis (PBC) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Primary Biliary Cholangitis treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Primary Biliary Cholangitis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Primary Biliary Cholangitis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Primary Biliary Cholangitis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Primary Biliary Cholangitis therapeutic market.

Primary Biliary Cholangitis (PBC) Therapeutics Landscape

There are approx. 28+ key companies developing therapies for Primary Biliary Cholangitis. Currently, Genfit is leading the therapeutics market with its Primary Biliary Cholangitis drug candidates in the most advanced stage of clinical development.

Primary Biliary Cholangitis (PBC) Companies Actively Working in the Therapeutic Market Include:

  • Genfit

  • CymaBay Therapeutics

  • Mirum Pharmaceuticals

  • Gilead Sciences

  • Eli Lilly and Company

  • Future Medicine

  • Ohara Pharmaceutical

  • Zydus Cadila

  • MYR Pharma

  • Selecta Biosciences

And Many Others

Emerging and Marketed Primary Biliary Cholangitis Drugs Covered in the Report Include:

  • Elafibranor: Genfit

  • Seladelpar: CymaBay Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Primary Biliary Cholangitis Companies Working in the Market @

Analysis of Emerging Primary Biliary Cholangitis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Primary Biliary Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Primary Biliary Cholangitis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Primary Biliary Cholangitis Treatment Patterns

4. Primary Biliary Cholangitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Primary Biliary Cholangitis Late Stage Products (Phase-III)

7. Primary Biliary Cholangitis Mid-Stage Products (Phase-II)

8. Primary Biliary Cholangitis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Primary Biliary Cholangitis Discontinued Products

13. Primary Biliary Cholangitis Product Profiles

14. Major Primary Biliary Cholangitis Companies in the Market

15. Key Products in the Primary Biliary Cholangitis Therapeutics Segment

16. Dormant and Discontinued Products

17. Primary Biliary Cholangitis Unmet Needs

18. Primary Biliary Cholangitis Future Perspectives

19. Primary Biliary Cholangitis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Other Trending Healthcare Reports By DelveInsight

Morquio Syndrome Market

“Morquio Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Morquio Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Morquio Syndrome market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles